Programme Thesis
scientifyRESEARCH is an open-access, curated funding database that aggregates global research grants, fellowships, and awards across all disciplines and career stages — it is not itself a funder. The URL https://www.scientifyresearch.org/all-funding-neuroscience/ is a filtered listing page showing 100+ neuroscience opportunities from many independent funders. The page content extracted for this brief surfaces eight specific live programmes: CurePSP New Investigator Award, NCL-Stiftung Rare-To-Common Prize, Simons Junior Fellows, NIMH R33, Else Kröner Excellence Grants, NCL-Stiftung Doctoral Fellowships, NAM S&T Centre Fellowship, and Tourette Association Consortia Grants. Each has entirely separate eligibility rules, application portals, and review panels.
Selection Criteria
• CurePSP NIA (most accessible; Oct 15, 2026): Early career investigators at assistant professor or 'equivalent independent research position' level; US or international; focus STRICTLY on PSP or CBD (tauopathies) — either fundamental neurobiology or translational biomarkers/therapeutics; reviewed by CurePSP Scientific Advisory Board; up to $100K / 1–2 years.
• NCL-Stiftung Rare-To-Common Prize (LOI Aug 31, full Oct 31, 2026): REQUIRES TWO collaborating institutions — one CLN3/NCL specialist + one common neurodegeneration partner; must be institutionally affiliated; €200K; focus on bridging Batten disease with Alzheimer's/lysosomal dysfunction/retinal degeneration.
• Simons Junior Fellows (Sep 30, 2026): Requires physical presence at a Simons-affiliated NYC-area institution; highly competitive, typically postdocs; salary + $10K allowance.
• NIMH R33 (Oct 15, 2026): R33 phase of R61/R33 mechanism; clinical trial required; typically requires US academic or nonprofit institutional affiliation and IRB infrastructure.
• Else Kröner Excellence Grants (July 31, 2026): Physician-scientists at German institutions; €350K; medicine focus; German residency essentially required.
• NCL Doctoral Fellowships (Aug 31, 2026): PhD-enrolled candidates only.
• NAM S&T Centre Fellowship: India-based, travel/accommodation only, STEM developing-world focus.
Past Winners / Cohort Profiles
scientifyRESEARCH does not itself select winners. For the individual programmes: CurePSP NIA past recipients have been US and European postdocs/junior faculty at academic medical centers (e.g., UCSF, UCL, Johns Hopkins) publishing on tau pathology, synaptic dysfunction, and neuroinflammation in PSP/CBD specifically. The Simons Junior Fellows cohort (2024 class publicly announced) comprises postdocs hosted at NYC institutions — Rockefeller, NYU, Columbia, Mt Sinai — in computational neuroscience, physics, biology, and math. NCL-Stiftung has funded European academic labs (Germany, UK, Netherlands) specialising in lysosomal storage disease and cellular ageing. None of these programmes have a disclosed LMIC or independent-researcher track record.
Ideal Candidate Fingerprint
For the CurePSP New Investigator Award (the only listed programme that is worldwide, early-career, and accessible without a PhD): an early-stage investigator (postdoc or junior faculty equivalent) at an academic or non-profit research institution, with preliminary data on PSP or CBD mechanisms, seeking seed funding to generate pilot data for an R01 or equivalent. For the Simons Junior Fellows: a PhD-holding researcher physically relocating to New York City with a quantitative or theoretical background. The programmes collectively skew toward institutionally-affiliated, neurodegeneration-focused, PhD-holding researchers in high-income research settings.
Recommended Framing
Eniola should approach this URL as a DISCOVERY TOOL to find better-matched opportunities rather than as a single programme to apply to. Among the eight listings, the only one where a creative case could be constructed is the CurePSP New Investigator Award — her Bayesian MCMC validation pipeline, ODE/RK45 pharmacological modelling, and CCT clinical trial architecture could be reframed toward tau propagation modelling or synaptic threshold dynamics in PSP/CBD if she could demonstrate genuine mechanistic overlap; however, this would require an authentic scientific pivot, not cosmetic reframing. More strategically, she should use scientifyRESEARCH's premium filters (career stage: early-career/pre-PhD, eligibility: LMIC, discipline: addiction neuroscience/computational pharmacology) to surface the minority of listings that are actually open to independent international researchers — the eight programmes shown on this page are collectively a poor eligibility fit.
Watch Out
CRITICAL — scientifyRESEARCH is a database, not a funder: there is no application to submit to this URL itself; CV/cover letter/proposal materials would apply to individual listed programmes, not to the listing page.
• Topic mismatch: Every substantive listed programme (CurePSP, NCL-Stiftung, NIMH R33) focuses on neurodegeneration (PSP, CBD, NCL/Batten, tauopathies) — Eniola's CCT model addresses reward-memory encoding in addiction, a distinct domain with only loose mechanistic overlap.
• CurePSP career-stage risk: The RFA specifies 'assistant professor, research assistant professor, or equivalent independent research position' — Eniola's current title is National Product Manager (Synthcare), which is a commercial role unlikely to qualify; her independent researcher status at ZYCO would need to be formally articulated and accepted as equivalent.
• NCL-Stiftung Rare-To-Common: Requires TWO collaborating institutions, CLN3 expertise Eniola does not have, and LOI by Aug 31, 2026 — extremely imminent with no existing CLN3 collaborator on her profile.
• Simons Junior Fellows: NYC physical residence required; Eniola is in Lagos, Nigeria.
• NIMH R33: Requires a completed R61 phase (or equivalent) and clinical trial infrastructure — not accessible as a first application.
• Else Kröner Excellence Grants: Deadline July 31, 2026 — likely already passed at time of this brief; German institution required.
• NCL Doctoral Fellowships: Requires active PhD enrolment — Eniola is applying for October 2026 start, not yet enrolled.